MANKIND PHARMA Financial Statement Analysis
|
||
|
The Revenues of MANKIND PHARMA have increased by 16.96% YoY .
The Earnings Per Share (EPS) of MANKIND PHARMA has decreased by -3.96 % YoY. |
||
MANKIND PHARMA Last 5 Annual Financial Results
[BOM: 543904|NSE : MANKIND]
| Consolidated | Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 |
|---|---|---|---|---|---|
| Revenues | ₹14,278 Cr | ₹12,207 Cr | ₹10,260 Cr | ₹8,749 Cr | ₹7,782 Cr |
| Expenses | ₹10,655 Cr | ₹9,187 Cr | ₹7,745 Cr | ₹6,848 Cr | ₹5,791 Cr |
| Operating Profit (Excl OI) | ₹3,622 Cr | ₹3,020 Cr | ₹2,515 Cr | ₹1,902 Cr | ₹1,991 Cr |
| Other Income | ₹359 Cr | ₹537 Cr | ₹280 Cr | ₹129 Cr | ₹196 Cr |
| Interest | ₹644 Cr | ₹432 Cr | ₹34 Cr | ₹46 Cr | ₹60 Cr |
| Depreciation | ₹886 Cr | ₹621 Cr | ₹378 Cr | ₹326 Cr | ₹167 Cr |
| Profit Before Tax | ₹2,333 Cr | ₹2,516 Cr | ₹2,398 Cr | ₹1,671 Cr | ₹1,975 Cr |
| Profit After Tax | ₹1,938 Cr | ₹2,007 Cr | ₹1,941 Cr | ₹1,310 Cr | ₹1,453 Cr |
| Consolidated Net Profit | ₹1,913 Cr | ₹1,991 Cr | ₹1,913 Cr | ₹1,282 Cr | ₹1,433 Cr |
| Earnings Per Share (Rs) | ₹46.34 | ₹48.25 | ₹47.75 | ₹32.00 | ₹35.78 |
| PAT Margin (%) | 12.98 | 15.83 | 18.18 | 14.38 | 18.00 |
| ROE(%) | 12.69 | 16.98 | 23.14 | 19.27 | 26.72 |
| ROCE(%) | 13.24 | 18.32 | 28.35 | 23.49 | 33.96 |
| Total Debt/Equity(x) | 0.37 | 0.58 | 0.02 | 0.02 | 0.14 |
Key Financials |
||
| Market Cap | : | ₹ 97,757.1 Cr |
| Revenue (TTM) | : | ₹ 14,737.9 Cr |
| Net Profit(TTM) | : | ₹ 2,055.1 Cr |
| EPS (TTM) | : | ₹ 49.8 |
| P/E (TTM) | : | 47.6 |
| Industry Peers & Returns | 1W | 1M | 1Y |
| MANKIND PHARMA | -0.6% | -5.2% | -4% |
| SUN PHARMACEUTICAL INDUSTRIES | 1.8% | -1.6% | 16.5% |
| DIVIS LABORATORIES | -1.2% | 17.3% | 38.7% |
| TORRENT PHARMACEUTICALS | -2.3% | -2% | 33.6% |
| CIPLA | 0.2% | 1.7% | -8.8% |
| DR REDDYS LABORATORIES | 1.2% | 3.6% | -7% |
| LUPIN | -1.6% | -7.6% | 11.4% |
| ZYDUS LIFESCIENCES | -1.4% | -0.7% | 13.5% |
| AUROBINDO PHARMA | -1.8% | 5.1% | 48.6% |
MANKIND PHARMA Revenues
[BOM: 543904|NSE : MANKIND]
| Y-o-Y | 16.96 % |
| 5 Yr CAGR | 16.39 % |
| Years | Revenues | % Change | |
|---|---|---|---|
| Mar2026 | ₹14,278 Cr | 16.96 | |
| Mar2025 | ₹12,207 Cr | 18.98 | |
| Mar2024 | ₹10,260 Cr | 17.27 | |
| Mar2023 | ₹8,749 Cr | 12.44 | |
| Mar2022 | ₹7,782 Cr | - | |
MANKIND PHARMA Operating Profit
[BOM: 543904|NSE : MANKIND]
| Y-o-Y | 19.93 % |
| 5 Yr CAGR | 16.15 % |
| Years | Operating Profit | % Change | |
|---|---|---|---|
| Mar2026 | ₹3,622 Cr | 19.93 | |
| Mar2025 | ₹3,020 Cr | 20.09 | |
| Mar2024 | ₹2,515 Cr | 32.24 | |
| Mar2023 | ₹1,902 Cr | -4.45 | |
| Mar2022 | ₹1,991 Cr | - | |
| Operating Margins | |
|---|---|
| Y-o-Y | 2.55 % |
| 5 Yr CAGR | -0.21 % |
| Years | Operating Margin% | % Change | |
|---|---|---|---|
| Mar2026 | 25.37% | 2.55 | |
| Mar2025 | 24.74% | 0.94 | |
| Mar2024 | 24.51% | 12.74 | |
| Mar2023 | 21.74% | -15.01 | |
| Mar2022 | 25.58% | - | |
MANKIND PHARMA Profit After Tax
[BOM: 543904|NSE : MANKIND]
| Y-o-Y | -3.92 % |
| 5 Yr CAGR | 7.48 % |
| Years | Profit After Tax | % Change | |
|---|---|---|---|
| Mar2026 | ₹1,913 Cr | -3.92 | |
| Mar2025 | ₹1,991 Cr | 4.08 | |
| Mar2024 | ₹1,913 Cr | 49.23 | |
| Mar2023 | ₹1,282 Cr | -10.58 | |
| Mar2022 | ₹1,433 Cr | - | |
| PAT Margins | |
|---|---|
| Y-o-Y | -18.00 % |
| 5 Yr CAGR | -7.85 % |
| Years | PAT Margin(%) | % Change | |
|---|---|---|---|
| Mar2026 | 12.98 % | -18.00 | |
| Mar2025 | 15.83 % | -12.93 | |
| Mar2024 | 18.18 % | 26.43 | |
| Mar2023 | 14.38 % | -20.11 | |
| Mar2022 | 18 % | - | |
MANKIND PHARMA Earnings Per Share (EPS)
[BOM: 543904|NSE : MANKIND]
| Y-o-Y | -3.96 % |
| 5 Yr CAGR | 6.68 % |
| Years | EPS | % Change | |
|---|---|---|---|
| Mar2026 | ₹46 | -3.96 | |
| Mar2025 | ₹48 | 1.05 | |
| Mar2024 | ₹48 | 49.22 | |
| Mar2023 | ₹32 | -10.56 | |
| Mar2022 | ₹36 | - | |
MANKIND PHARMA Return on Capital Employed (ROCE)
[BOM: 543904|NSE : MANKIND]
| Y-o-Y | -27.73 % |
| 5 Yr CAGR | -20.98 % |
| Years | ROCE | % Change | |
|---|---|---|---|
| Mar2026 | 13.24% | -27.73 | |
| Mar2025 | 18.32% | -35.38 | |
| Mar2024 | 28.35% | 20.69 | |
| Mar2023 | 23.49% | -30.83 | |
| Mar2022 | 33.96% | - | |
MANKIND PHARMA Share Price vs Sensex
| Current Share Price | : | ₹2,367.0 |
| Current MarketCap | : | ₹ 97,757.1 Cr |
| Updated EOD on | : | Aug 25,2026 |
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| MANKIND PHARMA | -0.6% |
-5.2% |
-4% |
| SENSEX | 0.5% |
2.1% |
-4.5% |
MANKIND PHARMA related INDICES
| BSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| BSE SELECT IPO INDEX | 1.7% | 8.1% | 0.3% |
| BSE 150 MIDCAP INDEX | 0.6% | 4% | 9.7% |
| BSE 200 EQUAL WEIGHT | 0.5% | 3% | 8.3% |
| BSE 250 LARGEMIDCAP INDEX | 0.5% | 2.8% | 2% |
| BSE 200 | 0.5% | 2.6% | 1.5% |
| NSE Indices | 1W | 1M | 1Y |
|---|---|---|---|
| NIFTY MIDCAP 50 | 1.1% | 4% | 14.1% |
| NIFTY MIDCAP 100 | 1% | 4.1% | 12.3% |
| NIFTY HEALTHCARE INDEX | 0.8% | 2.2% | 13.4% |
| NIFTY PHARMA | 0.8% | 4% | 20% |
| NIFTY INDIA FPI 150 | 0.7% | 2.9% | 3.4% |
You may also like the below Video Courses
FAQ about MANKIND PHARMA Financials
How the annual revenues of MANKIND PHARMA have changed ?
The Revenues of MANKIND PHARMA have increased by 16.96% YoY .
How the Earnings per Share (EPS) of MANKIND PHARMA have changed?
The Earnings Per Share (EPS) of MANKIND PHARMA has decreased by -3.96 % YoY .
Check out Intrinsic Value of Peers of MANKIND PHARMA
Compare Stock Analytics of Peers of MANKIND PHARMA
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
SUN PHARMACEUTICAL INDUSTRIES LTD vs DIVIS LABORATORIES LTD vs TORRENT PHARMACEUTICALS LTD
CIPLA LTD vs DR REDDYS LABORATORIES LTD vs
